Kidney Transplant Rejection Study Using Novel Blood Test

Utilization of dd-cfDNA to Assess for Rejection

Protocol Description

This study uses blood and DNA testing to learn more about rejection after a child’s kidney transplant. Researchers believe the blood test can help them to determine if a kidney biopsy or other treatments are needed. The use of dd-cfDNA (donor-derived cell-free DNA) will help in identifying patients needing a renal biopsy due to an elevated serum Cr or at high risk for rejection. It may also be useful in assessing the response to therapy in patients with biopsy-proven 1B rejection.

Eligibility Criteria

The study is accepting participants who have experienced or are likely to experience rejection after their kidney transplant.
Males and Females: Up through age 20


During visits following kidney transplant when LDL apheresis treatments are being administered, extra blood draws will be taken through the existing catheter in place for the LDL apheresis treatment. The blood draws will be done 6 times over a period of 6 months.
Visits: None beyond normal follow up care for kidney transplant
Duration: 6 months

Status: Open to Enrollment

Source(s) of Support


Additional Information

Nephrology Research

Primary Investigator

Michael Moritz, MD

Contact Information

For more information about the study or enrollment, please contact:
Vibha Chauhan, PhD, CCRP, CCRC